Ryan Bartolucci Sells 4,116 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 4,116 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $181,392.12. Following the transaction, the chief accounting officer directly owned 74,041 shares in the company, valued at $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Down 0.7%

Tempus AI stock opened at $46.18 on Friday. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The firm has a market cap of $8.29 billion, a PE ratio of -26.85 and a beta of 3.99. The firm’s 50 day moving average price is $48.89 and its two-hundred day moving average price is $59.29.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same quarter last year, the business posted ($0.24) EPS. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. On average, research analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Guggenheim reduced their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. JPMorgan Chase & Co. cut their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Morgan Stanley reduced their target price on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. HC Wainwright dropped their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, Mizuho initiated coverage on shares of Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and an average target price of $68.64.

Institutional Investors Weigh In On Tempus AI

Large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. raised its position in shares of Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after purchasing an additional 162 shares during the period. US Bancorp DE grew its stake in Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after buying an additional 176 shares during the last quarter. Legacy Bridge LLC raised its holdings in Tempus AI by 1.6% in the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after acquiring an additional 193 shares during the period. Truist Financial Corp boosted its holdings in Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after acquiring an additional 194 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Tempus AI by 3.5% in the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after purchasing an additional 219 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.